210 related articles for article (PubMed ID: 16825437)
1. Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
Karppinen SM; Barkardottir RB; Backenhorn K; Sydenham T; Syrjäkoski K; Schleutker J; Ikonen T; Pylkäs K; Rapakko K; Erkko H; Johannesdottir G; Gerdes AM; Thomassen M; Agnarsson BA; Grip M; Kallioniemi A; Kere J; Aaltonen LA; Arason A; Møller P; Kruse TA; Borg A; Winqvist R
J Med Genet; 2006 Nov; 43(11):856-62. PubMed ID: 16825437
[TBL] [Abstract][Full Text] [Related]
2. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
[TBL] [Abstract][Full Text] [Related]
3. The BARD1 Cys557Ser variant and risk of familial breast cancer in a South-American population.
Gonzalez-Hormazabal P; Reyes JM; Blanco R; Bravo T; Carrera I; Peralta O; Gomez F; Waugh E; Margarit S; Ibañez G; Santos JL; Jara L
Mol Biol Rep; 2012 Aug; 39(8):8091-8. PubMed ID: 22544576
[TBL] [Abstract][Full Text] [Related]
4. BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.
Vahteristo P; Syrjäkoski K; Heikkinen T; Eerola H; Aittomäki K; von Smitten K; Holli K; Blomqvist C; Kallioniemi OP; Nevanlinna H
Eur J Hum Genet; 2006 Feb; 14(2):167-72. PubMed ID: 16333312
[TBL] [Abstract][Full Text] [Related]
5. BARD1 and breast cancer in Poland.
Jakubowska A; Cybulski C; Szymańska A; Huzarski T; Byrski T; Gronwald J; Debniak T; Górski B; Kowalska E; Narod SA; Lubiński J
Breast Cancer Res Treat; 2008 Jan; 107(1):119-22. PubMed ID: 17333333
[TBL] [Abstract][Full Text] [Related]
6. Lack of association between BARD1 Cys557Ser variant and breast cancer risk: a meta-analysis of 11,870 cases and 7,687 controls.
Ding DP; Zhang Y; Ma WL; He XF; Wang W; Yu HL; Guo YB; Zheng WL
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1463-8. PubMed ID: 21809034
[TBL] [Abstract][Full Text] [Related]
7. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Spurdle AB; Marquart L; McGuffog L; Healey S; Sinilnikova O; Wan F; Chen X; Beesley J; Singer CF; Dressler AC; Gschwantler-Kaulich D; Blum JL; Tung N; Weitzel J; Lynch H; Garber J; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Conroy D; Evans DG; Lalloo F; Eeles R; Izatt L; Davidson R; Chu C; Eccles D; Selkirk CG; Daly M; Isaacs C; Stoppa-Lyonnet D; Sinilnikova OM; Buecher B; Belotti M; Mazoyer S; Barjhoux L; Verny-Pierre C; Lasset C; Dreyfus H; Pujol P; Collonge-Rame MA; ; Rookus MA; Verhoef S; Kriege M; Hoogerbrugge N; Ausems MG; van Os TA; Wijnen J; Devilee P; Meijers-Heijboer HE; Blok MJ; Heikkinen T; Nevanlinna H; Jakubowska A; Lubinski J; Huzarski T; Byrski T; Durocher F; Couch FJ; Lindor NM; Wang X; Thomassen M; Domchek S; Nathanson K; Caligo M; Jernström H; Liljegren A; Ehrencrona H; Karlsson P; ; Ganz PA; Olopade OI; Tomlinson G; Neuhausen S; Antoniou AC; Chenevix-Trench G; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1032-8. PubMed ID: 21393566
[TBL] [Abstract][Full Text] [Related]
8. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
De Brakeleer S; De Grève J; Loris R; Janin N; Lissens W; Sermijn E; Teugels E
Hum Mutat; 2010 Mar; 31(3):E1175-85. PubMed ID: 20077502
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
Ghimenti C; Sensi E; Presciuttini S; Brunetti IM; Conte P; Bevilacqua G; Caligo MA
Genes Chromosomes Cancer; 2002 Mar; 33(3):235-42. PubMed ID: 11807980
[TBL] [Abstract][Full Text] [Related]
10. Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
Ratajska M; Antoszewska E; Piskorz A; Brozek I; Borg Å; Kusmierek H; Biernat W; Limon J
Breast Cancer Res Treat; 2012 Jan; 131(1):89-97. PubMed ID: 21344236
[TBL] [Abstract][Full Text] [Related]
11. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract][Full Text] [Related]
12. The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis.
Johnatty SE; Beesley J; Chen X; Hopper JL; Southey MC; Giles GG; Goldgar DE; Chenevix-Trench G; Spurdle AB; ;
Breast Cancer Res Treat; 2009 May; 115(1):145-50. PubMed ID: 18481171
[TBL] [Abstract][Full Text] [Related]
13. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
14. Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer.
Karppinen SM; Heikkinen K; Rapakko K; Winqvist R
J Med Genet; 2004 Sep; 41(9):e114. PubMed ID: 15342711
[No Abstract] [Full Text] [Related]
15. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.
Sauer MK; Andrulis IL
J Med Genet; 2005 Aug; 42(8):633-8. PubMed ID: 16061562
[TBL] [Abstract][Full Text] [Related]
16. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
[TBL] [Abstract][Full Text] [Related]
17.
Rofes P; Del Valle J; Torres-Esquius S; Feliubadaló L; Stradella A; Moreno-Cabrera JM; López-Doriga A; Munté E; De Cid R; Campos O; Cuesta R; Teulé Á; Grau È; Sanz J; Capellá G; Díez O; Brunet J; Balmaña J; Lázaro C
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33498765
[TBL] [Abstract][Full Text] [Related]
18. Literature Review of
Alenezi WM; Fierheller CT; Recio N; Tonin PN
Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32726901
[TBL] [Abstract][Full Text] [Related]
19. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
